| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2802728703014 | 272870301 | CUBICIN PD.I.S.INF 350MG/VIAL (50MG/ML) BTx 1VIAL | 69.95 | 73.38 | 93.34 |
| 05/2018 | 2802728704011 | 272870401 | CUBICIN PD.I.S.INF 500MG/VIAL (50MG/ML) BTx 1VIAL | 98.22 | 103.03 | 126.68 |
For the treatment of complicated skin and skin structure infections caused by susceptible strains of Gram-positive microorganisms.
Daptomycin appears to bind or insert into the outer membrane of gram positive bacteria. The binding and integration of daptomycin into the cell membrane is calcium dependent. Calcium ions cause a conformational change in daptomycin, augmenting its amphipathicity (hydrophilic head group and hydrophobic tail group), leading to incorporation into the cell membrane. This binding causes rapid depolarisation, resulting in a loss of membrane potential leading to inhibition of protein, DNA and RNA synthesis, which results in bacterial cell death. The bactericidal activity of daptomycin is concentration-dependent. There is in vitro evidence of synergy with β-lactam antibiotics.
7 days
Daptomycin is excreted primarily by the kidney. In a mass balance study of 5 healthy subjects using radiolabeled daptomycin, approximately 78% of the administered dose was recovered from urine based on total radioactivity (approximately 52% of the dose based on microbiologically active concentrations) and 5.7% of the dose was recovered from feces (collected for up to 9 days) based on total radioactivity. Because renal excretion is the primary route of elimination, dosage adjustment is necessary in patients with severe renal insufficiency (CLCR <30 mL/min)
* 0.1 L/Kg [healthy adult subjects]